ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/glioma/high-grade-glioma
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Head & neck and Neurological / Glioma - High-grade glioma
21
trial(s) found.
NCT07739017
Advanced
Phase 1
Not yet recruiting
A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma (
OPAL
)
OLIG2 inhibitor
radiotherapy
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT07712770
Radonc
Phase 1
Not yet recruiting
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (
PRECISE
)
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT07100730
Radonc
Phase 3
Recruiting
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3]) (
IPAX-BrIGHT
)
alkylating agent
radioiodine conjugate
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06926075
Advanced
Phase 1 / Phase 2
Recruiting
An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Private Hospital
2228 - Miranda - Southside Cancer Care Centre
NCT06914128
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
PRMT5 inhibitor
NOT Glioblastoma
NOT High-grade glioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
NCT06816927
Advanced
Phase 2
Recruiting
A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (
GIANT
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Glioblastoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06333899
Paed
Phase 1
Recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
CONNECT-TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT06132438
Advanced
Phase 1
Recruiting
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (
INTERROGATE-GBM
)
Temozolomide
alkylating agent
cancer therapy
cytotoxic chemotherapy
Glioblastoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2170 - Liverpool - Liverpool Hospital
NCT05843253
Paed
Phase 2
Recruiting
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
alkylating agent
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05839379
Paed
Recruiting
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma (
CONNECT-TarGeT-SCR
)
Anaplastic astrocytoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
Dianhydrogalactitol
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
ACTRN12626000036314
Radonc
Phase 3
Not yet recruiting
To determine whether hypofractionated radiotherapy (HF-RT) combined with concurrent and adjuvant temozolomide (TMZ) provides survival outcomes that are not inferior to those of conventional fractionated radiotherapy (CF-RT) with concurrent and adjuvant TMZ in adults with newly diagnosed Grade 4 Glioblastoma (
CONCISE
)
alkylating agent
radiotherapy
Central nervous system cancer
Glioblastoma
ACTRN12625001269426
Curative
Phase 1 / Phase 2
Not yet recruiting
A Phase 1b/2 Study to Assess the Safety and Efficacy of Neoadjuvant Trametinib and Pembrolizumab in Patients with Newly Diagnosed Malignant Glioma
MEK inhibitor
anti-PD-1 monoclonal antibody
Glioblastoma
Malignant glioma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625001238460
Advanced
Phase 2
Not yet recruiting
PRIME
: A Phase 0/II open-label study of perioperative PRMT5 Inhibition with BMS-986504 in patients with recurrent MTAP-deleted glioblastoma
PRMT5 inhibitor,MTA-co-operative
Glioblastoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12625000779471
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Study of EGFR-targeted EDVs Carrying Doxorubicin (E-EDV-Dox) Combined with EDVs Carrying a-Galactosyl Ceramide (EDV-GC) in People with Recurrent Glioblastoma. (
ENG20
)
anthracycline
Glioblastoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACTRN12624001484538
Advanced
Phase 2
Recruiting
Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM). (
GBMI12
)
Ifosfamide
Radiotherapy
Temozolomide
alkylating agent
cancer therapy
cytotoxic chemotherapy
Glioblastoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4120 - Greenslopes - Greenslopes Private Hospital
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP1/2 inhibitor
PARP1 inhibitor
PARP2 inhibitor
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP1/2 inhibitor
PARP1 inhibitor
PARP2 inhibitor
PARP inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622001201763
Advanced
Phase 2
Recruiting
Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (
TRAS-GB
) Trial
Metformin
Propranolol
antihypertensives
beta-adrenergic blocker
biguanide antihyperglycaemic agent
Glioblastoma
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12612001050842
Advanced
Phase 1
Not yet recruiting
Valproate and MetformIn in GlioBlastoma multiformE Study: A single-arm trial to assess safety and feasibility –
VIBE
1
HDAC inhibitor
biguanide antihyperglycaemic agent
Central nervous system cancer
Glioblastoma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Not yet recruiting (6)
Recruitment Country and State
VIC (11)
NSW (11)
QLD (8)
WA (6)
NZ (4)
SA (3)
TAS (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (4)
Phase 2 (7)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (13)
Radonc (4)
Paed (3)
Curative (1)
Cancer Therapy Class
PD-1
14%
PD-1/PD-L1
14%
mTOR
14%
mTORC1
14%
PRMT5
10%
PI3K
10%
PI3K delta
10%
PI3Kalpha
10%
mTORC2
10%
PARP
10%
hGIIA-vimentin
5%
LAG3
5%
ALK
5%
DPD
5%
ROS1
5%
orotate phosphoribosyltransferase
5%
CDK4
5%
CDK6
5%
ATM
5%
FGFR
5%
FGFR1
5%
FGFR1/2/3
5%
FGFR2
5%
FGFR3
5%
FGFR4
5%
KIT
5%
PDGFR
5%
RET
5%
VEGFR
5%
MET
5%
MEK
5%
AR
5%
CYP17A1
5%
HMG-CoA reductase
5%
VEGF
5%
androgen axis
5%
oestrogen axis
5%
CTLA4
5%
XPO1
5%
HDAC
5%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2031 - Randwick - Sydney Children's Hospital (3)
4101 - South Brisbane - Queensland Children's Hospital (3)
6009 - Perth - Perth Children's Hospital (3)
NZ.1023 - Grafton - Starship Children's Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (2)
3066 - Epping - Northern Hospital (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
4215 - Southport - Gold Coast University Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2217 - Kogarah - St George Private Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
Cancer Type
Cancer
Solid tumour
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Glioblastoma
Anaplastic astrocytoma
Gastrointestinal cancer
Lung cancer
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Thoracic cancer
Upper gastrointestinal cancer
Urogenital cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Gynaecological cancer
Male genital cancers
Ovarian cancer
Prostate cancer
Non-small cell lung cancer
Breast cancer
Skin cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Diffuse midline glioma
Diffuse hemispheric glioma
Carcinoma
Colon adenocarcinoma
Colorectal adenocarcinoma
Colorectal cancer
Endocrine gland cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Kidney cancer
Lower gastrointestinal cancer
MET:alteration
MET:fusion
Neuroendocrine carcinoma
Oesophageal cancer
Thyroid cancer
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Low-grade glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy